🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to researchers.

An International Challenge

The sexually transmitted infection are on the rise worldwide, with figures suggesting in excess of 82 million new cases each year. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone marks a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

As per findings published in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The trial enrolled hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians treating patients have expressed positive views. Access to a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is deemed vital to reduce the burden of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.